Changes in HCMV immune cell frequency and phenotype are associated with chronic lung allograft dysfunction.
CD8 T cells
CMV
HCMV immunity
HCMV infection
HLA-E
UL40
chronic lung allograft dysfunction
transplantation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
01
2023
accepted:
10
04
2023
medline:
17
5
2023
pubmed:
16
5
2023
entrez:
15
5
2023
Statut:
epublish
Résumé
Human cytomegalovirus (HCMV) infection is common and often severe in lung transplant recipients (LTRs), and it is a risk factor associated with chronic lung allograft dysfunction (CLAD). The complex interplay between HCMV and allograft rejection is still unclear. Currently, no treatment is available to reverse CLAD after diagnosis, and the identification of reliable biomarkers that can predict the early development of CLAD is needed. This study investigated the HCMV immunity in LTRs who will develop CLAD. This study quantified and phenotyped conventional (HLA-A2pp65) and HLA-E-restricted (HLA-EUL40) anti-HCMV CD8 At M18 post-transplantation, HLA-EUL40 CD8 T responses were less frequently found in HCMV CLAD is associated with significant changes in anti-HCMV immune cell responses. Our findings propose that the presence of dysfunctional HCMV-specific HLA-E-restricted CD8 T cells together with post-infection changes in the immune cell distribution affecting NK and γδT cells defines an early immune signature for CLAD in HCMV
Sections du résumé
Background
Human cytomegalovirus (HCMV) infection is common and often severe in lung transplant recipients (LTRs), and it is a risk factor associated with chronic lung allograft dysfunction (CLAD). The complex interplay between HCMV and allograft rejection is still unclear. Currently, no treatment is available to reverse CLAD after diagnosis, and the identification of reliable biomarkers that can predict the early development of CLAD is needed. This study investigated the HCMV immunity in LTRs who will develop CLAD.
Methods
This study quantified and phenotyped conventional (HLA-A2pp65) and HLA-E-restricted (HLA-EUL40) anti-HCMV CD8
Results
At M18 post-transplantation, HLA-EUL40 CD8 T responses were less frequently found in HCMV
Conclusions
CLAD is associated with significant changes in anti-HCMV immune cell responses. Our findings propose that the presence of dysfunctional HCMV-specific HLA-E-restricted CD8 T cells together with post-infection changes in the immune cell distribution affecting NK and γδT cells defines an early immune signature for CLAD in HCMV
Identifiants
pubmed: 37187736
doi: 10.3389/fimmu.2023.1143875
pmc: PMC10175754
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143875Informations de copyright
Copyright © 2023 Rousselière, Delbos, Foureau, Reynaud-Gaubert, Roux, Demant, Le Pavec, Kessler, Mornex, Messika, Falque, Le Borgne, Boussaud, Tissot, Hombourger, Bressollette-Bodin and Charreau.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Transplantation. 2021 Nov 1;105(11):e156-e167
pubmed: 33724240
Int J Mol Sci. 2021 Dec 27;23(1):
pubmed: 35008688
Am J Transplant. 2004 Aug;4(8):1219-26
pubmed: 15268722
J Heart Lung Transplant. 2019 May;38(5):493-503
pubmed: 30962148
J Immunol. 2012 Nov 15;189(10):5082-8
pubmed: 23077239
Med Microbiol Immunol. 2019 Aug;208(3-4):365-373
pubmed: 30989333
Transplantation. 2014 Nov 15;98(9):1013-8
pubmed: 24837540
Front Immunol. 2017 Feb 09;8:105
pubmed: 28232834
Front Immunol. 2022 Dec 01;13:1063690
pubmed: 36532017
J Infect Dis. 2009 Nov 1;200(9):1415-24
pubmed: 19780672
J Neuroinflammation. 2020 May 20;17(1):161
pubmed: 32434524
Immunity. 2011 Sep 23;35(3):400-12
pubmed: 21943489
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
J Heart Lung Transplant. 2020 Nov;39(11):1300-1312
pubmed: 32962919
Am J Respir Crit Care Med. 2014 Feb 1;189(3):292-300
pubmed: 24354907
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11328-33
pubmed: 12167676
PLoS Pathog. 2018 Apr 30;14(4):e1007041
pubmed: 29709038
Thorax. 2019 Apr;74(4):397-404
pubmed: 30381399
J Heart Lung Transplant. 2021 Sep;40(9):900-904
pubmed: 34183227
Eur J Immunol. 2001 Dec;31(12):3687-93
pubmed: 11745389
Blood. 2007 Apr 1;109(7):2806-14
pubmed: 17179229
Mech Ageing Dev. 2016 Sep;158:14-22
pubmed: 26957355
J Heart Lung Transplant. 2018 Oct;37(10):1169-1183
pubmed: 30293613
Nat Commun. 2019 Nov 25;10(1):5350
pubmed: 31767837
Transplantation. 2019 Mar;103(3):493-501
pubmed: 30211828
J Pathol. 2015 Jan;235(2):288-97
pubmed: 25205255
Nat Commun. 2019 Nov 28;10(1):5415
pubmed: 31780669
Eur J Immunol. 2016 May;46(5):1168-79
pubmed: 26910859
J Infect Dis. 1999 Jan;179(1):1-8
pubmed: 9841815
Transplantation. 2016 Sep;100(9):1803-14
pubmed: 27257997
Front Immunol. 2015 Jan 21;6:3
pubmed: 25653652
Cells. 2023 Mar 14;12(6):
pubmed: 36980230
Transplantation. 2019 Aug;103(8):1689-1699
pubmed: 30461721
Front Immunol. 2017 Jul 24;8:892
pubmed: 28791027
Immunity. 2007 Oct;27(4):670-84
pubmed: 17950003
PLoS One. 2015 Aug 24;10(8):e0135972
pubmed: 26302084
J Heart Lung Transplant. 2019 Jan;38(1):5-16
pubmed: 30391193
Blood. 2012 Mar 15;119(11):2665-74
pubmed: 22180440
J Immunol. 2010 Jun 15;184(12):6790-8
pubmed: 20488796
J Heart Lung Transplant. 2017 Oct;36(10):1047-1059
pubmed: 28784324
Clin Transplant. 2019 Sep;33(9):e13512
pubmed: 30817026
Elife. 2020 Jun 08;9:
pubmed: 32510326
Am J Transplant. 2011 Oct;11(10):2190-6
pubmed: 21794087
Semin Immunol. 2014 Apr;26(2):145-51
pubmed: 24666761
Front Cell Infect Microbiol. 2020 Mar 31;10:130
pubmed: 32296651
Vaccine. 2015 Mar 17;33(12):1433-9
pubmed: 25659271